Insider Selling: Edwards Lifesciences Co. (NYSE:EW) CFO Sells $797,287.50 in Stock

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Trading Down 0.4 %

NYSE:EW opened at $70.90 on Friday. The company has a 50-day moving average price of $71.49 and a 200-day moving average price of $70.49. The stock has a market cap of $41.68 billion, a price-to-earnings ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.73.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EW. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. The Goldman Sachs Group increased their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $27,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $30,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.